The 17 references in paper A. Tatarsky R., А. Татарский Р. (2014) “Принципы выбора препаратов для лечения хронической обструктивной болезни легких согласно новым международным клиническим рекомендациям // Principles of medication choice for treatment of chronic obstructive pulmonary disease according to new international guidelines” / spz:neicon:pulmonology:y:2013:i:2:p:89-94

1
Глобальная инициатива по хронической обструктивной болезни легких. Пересмотр 2003 г. Пер. с англ. М.: Издательство "Атмосфера"; 2003.
(check this in PDF content)
2
Global initiative for chronic obstructive lung disease (GOLD); 2006.www.cgsmedicare.com
(check this in PDF content)
3
Global initiative for chronic obstructive lung disease (GOLD); 2011.www.cuidadosintensivos.net
(check this in PDF content)
4
Global initiative for chronic obstructive lung disease (GOLD); 2012. www.member.ghc.org
(check this in PDF content)
5
AgustíA., Celli B.Avoiding confusion in COPD: from risk factors to phenotypes to measures of disease characterization. Eur. Respir. J. 2011; 38: 749–751. DOI: 10.1183/ 09031936.00062211.
(check this in PDF content)
6
Chetta A., Zanini A., Foresi A. et al.Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone. Am. J. Respir. Crit. Care Med. 2003; 167 (5):
(check this in PDF content)
7
1–757. 7.Hoshino M.Comparison of effectiveness in ciclesonide and fluticasone propionate on small airway function in mild asthma. Allergol. Int. 2010; 59 (1): 59–66.
(check this in PDF content)
8
Lundbäck B., Ronmark E., Lindberg A. et al.Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. Respir. Med. 2006; 100 (1): 2–10.
(check this in PDF content)
9
Woolcock A.J., Bastiampillai S.A., Marks G.B., Keena V.A. The burden of asthma in Australia. Med. J. Aust. 2001; 175 (3): 141–145.
(check this in PDF content)
10
Авдеев С.Н. Антибактериальная терапия при обострении хроничеческой обструктивной болезни легких. Пульмонология 2010; 2: 96–106.
(check this in PDF content)
11
Cazzola W., MacNee F.J.Martinez. Outcomes for COPD pharmacological trials: from lung functions to biomarkers. Eur. Respir. J. 2008; 31 (2): 416–469.
(check this in PDF content)
12
Mahler D.A.The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2002; 110 (6, Suppl.): S298–S303.
(check this in PDF content)
13
Bateman E.D., Boushey H.A., Bousquet J. et al.Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med. 2004; 170 (8): 836–844.
(check this in PDF content)
14
Mahler D.A., Wire P., Horstman D. et al.Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166 (8): 1084–1091.
(check this in PDF content)
15
Vestbo J. New thinking and COPD. Ugeskr Laeger. 2003;
(check this in PDF content)
16
45): 4319. 16.Vestbo J.The TORCH (towards a revolution in COPD health) survival study protocol. TORCH Study Group. Eur. Respir. J. 2004; 24 (2): 206–210.
(check this in PDF content)
17
Calverley P.M., Anderson J.A., Celli B. et al.TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356 (8): 775–789. Информация об авторе
(check this in PDF content)